Akebia Therapeutics (AKBA) Non Operating Income (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Non Operating Income of -$4.7 million for Q1 2026, up 39.63% year-over-year from -$3.4 million in Q1 2025, and up 2.82% quarter-over-quarter from -$4.8 million in Q4 2025.
Akebia Therapeutics (AKBA) Non Operating Income (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Non Operating Income for 14 consecutive years, with -$4.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 39.63% year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$21.1 million (up 10.05% YoY), while the FY2025 annual figure was -$24.2 million, down 32.96% from the prior year.
- Non Operating Income rose to -$4.7 million in Q1 2026 per AKBA's latest filing, from -$4.8 million in the prior quarter.
- Across five years, Non Operating Income topped out at -$1.4 million in Q3 2023 and bottomed at -$7.8 million in Q1 2025.
- Historically, Non Operating Income has averaged -$4.0 million across 5 years, with a median of -$4.7 million in 2026.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 69.16% — and 2024, when it sank 384.98%.
- Akebia Therapeutics' Non Operating Income stood at -$1.6 million in 2022, then increased by 13.33% to -$1.4 million in 2023, then slumped by 384.98% to -$6.9 million in 2024, then advanced by 29.81% to -$4.8 million in 2025, then grew by 2.82% to -$4.7 million in 2026.
- Business Quant data shows AKBA's Non Operating Income at -$4.7 million in Q1 2026, -$4.8 million in Q4 2025, and -$4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.07 Mn |
| Mar 31, 2026 | -4.69 Mn |
| Dec 31, 2025 | -4.83 Mn |
| Sep 30, 2025 | -4.75 Mn |
| Jun 30, 2025 | -6.83 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Dec 31, 2024 | -6.88 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Jun 30, 2024 | -2.15 Mn |
| Mar 31, 2024 | -2.50 Mn |
| Dec 31, 2023 | -1.42 Mn |
| Sep 30, 2023 | -1.41 Mn |
| Jun 30, 2023 | -1.64 Mn |
| Mar 31, 2023 | -1.56 Mn |
| Dec 31, 2022 | -1.64 Mn |
| Sep 30, 2022 | -3.95 Mn |
| Jun 30, 2022 | -5.04 Mn |
| Mar 31, 2022 | -5.06 Mn |
| Dec 31, 2021 | -5.08 Mn |
| Sep 30, 2021 | -5.09 Mn |